HK1127913A1 - Method and compositions for treating hematological malignancies - Google Patents
Method and compositions for treating hematological malignanciesInfo
- Publication number
- HK1127913A1 HK1127913A1 HK09107295.8A HK09107295A HK1127913A1 HK 1127913 A1 HK1127913 A1 HK 1127913A1 HK 09107295 A HK09107295 A HK 09107295A HK 1127913 A1 HK1127913 A1 HK 1127913A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hematological malignancies
- compositions
- treating hematological
- compound
- salt
- Prior art date
Links
- 208000002250 Hematologic Neoplasms Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 organic acid salt Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Processing Of Solid Wastes (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80098306P | 2006-05-16 | 2006-05-16 | |
US83180506P | 2006-07-18 | 2006-07-18 | |
PCT/US2007/011726 WO2007136650A2 (en) | 2006-05-16 | 2007-05-16 | Method and compositions for treating hematological malignancies |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1127913A1 true HK1127913A1 (en) | 2009-10-09 |
Family
ID=38578698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09107295.8A HK1127913A1 (en) | 2006-05-16 | 2009-08-10 | Method and compositions for treating hematological malignancies |
Country Status (20)
Country | Link |
---|---|
US (3) | US20080039427A1 (xx) |
EP (1) | EP2020996B1 (xx) |
JP (2) | JP5544165B2 (xx) |
KR (1) | KR101424832B1 (xx) |
CN (1) | CN101442994B (xx) |
AT (1) | ATE534377T1 (xx) |
AU (1) | AU2007254309B2 (xx) |
BR (1) | BRPI0711646C1 (xx) |
CA (1) | CA2652048C (xx) |
CY (1) | CY1112377T1 (xx) |
DK (1) | DK2020996T3 (xx) |
EA (1) | EA016995B1 (xx) |
ES (1) | ES2377467T3 (xx) |
HK (1) | HK1127913A1 (xx) |
MX (1) | MX2008014665A (xx) |
NZ (1) | NZ572368A (xx) |
PL (1) | PL2020996T3 (xx) |
PT (1) | PT2020996E (xx) |
SI (1) | SI2020996T1 (xx) |
WO (1) | WO2007136650A2 (xx) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
NZ573360A (en) | 2006-05-04 | 2012-08-31 | Boehringer Ingelheim Int | Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine |
WO2007136650A2 (en) * | 2006-05-16 | 2007-11-29 | Gilead Sciences, Inc. | Method and compositions for treating hematological malignancies |
TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
JP2012502081A (ja) | 2008-09-10 | 2012-01-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連症状の治療のための組み合わせ治療 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
TWI508965B (zh) | 2008-12-23 | 2015-11-21 | Boehringer Ingelheim Int | 有機化合物的鹽形式 |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
JP2013512229A (ja) | 2009-11-27 | 2013-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療 |
NZ602921A (en) | 2010-05-05 | 2016-01-29 | Boehringer Ingelheim Int | Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor |
MX2012014247A (es) | 2010-06-24 | 2013-01-18 | Boehringer Ingelheim Int | Terapia para la diabetes. |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
EP3517539B1 (en) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
EP3468562A1 (en) | 2016-06-10 | 2019-04-17 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
CN111989335B (zh) * | 2018-06-12 | 2023-06-13 | 四川科伦博泰生物医药股份有限公司 | 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途 |
CN112168829B (zh) * | 2020-09-24 | 2022-02-15 | 华南理工大学 | 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
ES2536972T5 (es) | 2000-07-21 | 2022-04-06 | Gilead Sciences Inc | Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos |
HUP0303128A3 (en) * | 2001-02-12 | 2008-03-28 | Wyeth Corp | Novel succinate salt of o-desmethyl-venlafaxine, process for preparation thereof, its use and pharmaceutical composition containing it |
EP1461040B1 (en) * | 2001-11-29 | 2006-03-15 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof |
HUP0402662A2 (hu) * | 2001-12-12 | 2005-05-30 | Pfizer Products Inc. | Az E-2-metoxi-N-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]kinazolin-6-il}-allil)acetamid sói, előállításuk és rák elleni alkalmazásuk |
WO2004037161A2 (en) * | 2002-05-13 | 2004-05-06 | Metabasis Therapeutics, Inc. | Cyclic prodrugs of pmea one of its analogues |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
NZ544715A (en) * | 2003-08-18 | 2009-09-25 | Lundbeck & Co As H | Succinate and malonate salt of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
PL1716162T3 (pl) | 2003-12-30 | 2011-02-28 | Gilead Sciences Inc | Fosfoniany, manofosfonamidy i bisfosfonamidy do leczenia chorób wirusowych |
CA2553455A1 (en) | 2004-01-21 | 2005-08-11 | Gilead Sciences, Inc. | Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis |
DE102005041860A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen |
AR058361A1 (es) * | 2005-12-16 | 2008-01-30 | Wyeth Corp | Composiciones lifolizadas de un compuesto de triazolopirimidina |
WO2007136650A2 (en) * | 2006-05-16 | 2007-11-29 | Gilead Sciences, Inc. | Method and compositions for treating hematological malignancies |
-
2007
- 2007-05-16 WO PCT/US2007/011726 patent/WO2007136650A2/en active Application Filing
- 2007-05-16 PT PT07794933T patent/PT2020996E/pt unknown
- 2007-05-16 US US11/803,822 patent/US20080039427A1/en not_active Abandoned
- 2007-05-16 AU AU2007254309A patent/AU2007254309B2/en active Active
- 2007-05-16 AT AT07794933T patent/ATE534377T1/de active
- 2007-05-16 ES ES07794933T patent/ES2377467T3/es active Active
- 2007-05-16 BR BRPI0711646A patent/BRPI0711646C1/pt active IP Right Grant
- 2007-05-16 EP EP07794933A patent/EP2020996B1/en active Active
- 2007-05-16 JP JP2009511052A patent/JP5544165B2/ja active Active
- 2007-05-16 US US12/298,987 patent/US20090258840A1/en not_active Abandoned
- 2007-05-16 EA EA200802333A patent/EA016995B1/ru unknown
- 2007-05-16 CA CA2652048A patent/CA2652048C/en active Active
- 2007-05-16 SI SI200730862T patent/SI2020996T1/sl unknown
- 2007-05-16 NZ NZ572368A patent/NZ572368A/en unknown
- 2007-05-16 PL PL07794933T patent/PL2020996T3/pl unknown
- 2007-05-16 MX MX2008014665A patent/MX2008014665A/es active IP Right Grant
- 2007-05-16 CN CN200780017637XA patent/CN101442994B/zh active Active
- 2007-05-16 DK DK07794933.7T patent/DK2020996T3/da active
- 2007-05-16 KR KR1020087030561A patent/KR101424832B1/ko active IP Right Grant
-
2009
- 2009-08-10 HK HK09107295.8A patent/HK1127913A1/xx unknown
-
2011
- 2011-03-23 US US13/070,179 patent/US8435969B2/en active Active
-
2012
- 2012-02-16 CY CY20121100159T patent/CY1112377T1/el unknown
-
2013
- 2013-01-17 JP JP2013006055A patent/JP2013100324A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1127913A1 (en) | Method and compositions for treating hematological malignancies | |
MY146111A (en) | Acylaminopyrazoles as fgfr inhibitors | |
MY150697A (en) | Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha | |
SG179418A1 (en) | Inhibitors of the hedgehog pathway | |
IL189694A0 (en) | Biphenyl derivatives and their use in treating hepatitis c | |
TR201900306T4 (tr) | Mek inhibitörlerini kullanma yöntemleri. | |
AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
JO2848B1 (en) | Organic compounds | |
EA200600689A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов raf киназы | |
MY150797A (en) | Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer | |
MX2009000657A (es) | Composiciones y metodos para el tratamiento de mucositis. | |
HK1093159A1 (en) | Monocyclic heterocycles as kinase inhibitors | |
HK1119699A1 (en) | Pyridopyrimidinone inhibitors of pi3kalpha | |
MX2009005934A (es) | Compuestos organicos. | |
TN2010000293A1 (en) | Thiazole derivatives used as pi 3 kinase inhibitors | |
MY155719A (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
UA85087C2 (xx) | Моноциклічні гетероцикли як інгібітори кінази$моноциклические гетероциклы - ингибиторы киназы | |
UA96969C2 (xx) | Ациламінопіразоли як fgfr інгібітори[ациламинопиразолы как fgfr ингибиторы | |
MX2011007165A (es) | Derivados de piridazinona. | |
BRPI0821114A2 (pt) | Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer | |
MX2009003102A (es) | INDOLILALQUILPIRIDIN-2-AMINAS PARA LA INHIBICION DE ß-SECRETASA. | |
MX2011007232A (es) | Derivados de benzotiazolona. | |
MY187188A (en) | Derivatives of di(phenylpropanoid) glycerol for the treatment of cancer | |
MY143200A (en) | Monocyclic heterocycles as kinase inhibitors | |
TW200732314A (en) | Substituted thiazoles and their use |